Sign in

    Vinicius Strano

    Director and Equity Analyst at UBS

    Vinicius Strano is a Director and Equity Analyst at UBS, specializing in Latin American consumer and retail sectors with coverage of major companies such as Natura &Co, Vivara, and Assaí. He is known for publishing actionable 'Buy' recommendations, including recent target prices for Vivara at R$ 32.00 and Assaí at R$ 13.00, and is noted for his market insights though specific third-party performance metrics and rankings are not publicly available. Strano began his career as an Equity Research Associate at Bank of America before joining UBS, where he is currently based in Zurich. His professional credentials are not explicitly listed, but his role indicates advanced expertise and regulatory compliance in securities research.

    Vinicius Strano's questions to Hypermarcas (HYPMY) leadership

    Vinicius Strano's questions to Hypermarcas (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano requested a breakdown of sell-out performance by business unit (generics, OTC, prescription) and the key drivers for achieving the 8% sell-out growth target for 2025. He also asked about the expected evolution of net debt.

    Answer

    Executive Breno Pires de Oliveira described Q1 sell-out growth as balanced, with generics slightly ahead. He cited upcoming launches for major brands like Neosaldina and a recovery in the pain killers market as key growth drivers. Executive Ramon Frutuoso Silva projected year-end net debt would be close to the prior year's level, as strong cash generation is offset by CapEx and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to Hypermarcas (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano from UBS requested a breakdown of sell-out performance across generics, OTC, and prescription drugs, and asked about the key drivers for achieving the 8% sell-out growth target for 2025. He also inquired about the expected evolution of net debt throughout the year.

    Answer

    Executive Breno Pires de Oliveira noted that Q1 sell-out growth was balanced across business units, with generics performing slightly above average. He cited important new launches, like muscular Neosaldina, as key drivers for accelerating sell-out. Executive Ramon Frutuoso Silva projected that year-end net debt would be close to the previous year's level, as strong cash generation is offset by significant investments and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to Hypermarcas (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano asked for a breakdown of sell-out performance across generics, OTC, and prescription drugs, and inquired about the key drivers for achieving the expected 8% sell-out growth in 2025. He also asked about the anticipated evolution of net debt.

    Answer

    Executive Breno Pires de Oliveira noted that Q1 sell-out growth was balanced across business units, with generics slightly higher. He cited upcoming launches, including muscular Neosaldina, as key drivers for accelerating sell-out. Executive Ramon Frutuoso Silva projected that net debt would end the year at a level similar to the previous year, as strong cash generation is offset by CapEx and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to Hypermarcas (HYPMY) leadership • Q1 2025

    Question

    Vinicius Strano asked for a breakdown of sell-out performance across generics, OTC, and prescription medications, the key drivers for accelerating sell-out to the expected 8% level in 2025, and the anticipated evolution of net debt throughout the year.

    Answer

    Breno Pires de Oliveira, an executive, described sell-out growth as balanced, with generics slightly above and skincare slightly below the 6% average. He cited new launches, like muscular Neosaldina, as key drivers for future acceleration. Ramon Frutuoso Silva, an executive, projected that year-end net debt would be close to the previous year's level, as higher cash generation is offset by CapEx and interest payments.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to ASAI leadership

    Vinicius Strano's questions to ASAI leadership • Q2 2024

    Question

    Asked about consumer price elasticity, whether it makes sense to invest more aggressively in price, the current stock levels of B2B customers, and the growth outlook for B2B versus B2C.

    Answer

    The company believes price is not the only factor for consumers; location and service are also key. As a low-price channel already, further margin reduction might not yield sufficient volume. B2B customers remain cautious with their inventory levels due to economic uncertainty and high interest rates, with no major stock-up trend observed.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to ASAI leadership • Q1 2024

    Question

    Asked about the behavior of B2B customers regarding restocking and the company's strategic plans for offering services, such as credit, to this segment.

    Answer

    The company stated that B2B customers are not building up stock due to stable inflation expectations and are using stores as immediate supply points. They confirmed they are considering an increase in service offerings for B2B customers to enhance loyalty and purchase frequency.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to ASAI leadership • Q4 2023

    Question

    Asked for details on the performance of organic (legacy) stores versus conversion stores, including same-store sales and cannibalization effects. Also questioned the drivers behind the reduction in stock levels and the outlook for working capital.

    Answer

    Cannibalization was about 2-3%, which was in line with the company's expectations. The legacy store network remains stable and is benefiting from the expertise and new services developed through the conversion project. The reduction in stock levels is a normalization after the initial stocking of many new stores; the current level is considered sustainable.

    Ask Fintool Equity Research AI

    Vinicius Strano's questions to ASAI leadership • Q3 2023

    Question

    Asked about potential levers for improving working capital, the normalized levels for inventory and supplier days, the customer mix (individual vs. legal entity) in converted stores, and the gross margin performance of these converted stores.

    Answer

    The company responded that working capital has already been optimized, with inventory days reduced and now stable at a healthy level around 44-45 days. Converted stores are performing well, with a higher gross margin than legacy stores and a growing mix of both B2C and B2B customers, the latter being driven by the increasing cost of door-to-door logistics for small businesses.

    Ask Fintool Equity Research AI